RT Journal Article SR Electronic T1 Detection of Hypervirulent Klebsiella pneumoniae from Clinical Samples in Tamil Nadu JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.02.19.23286158 DO 10.1101/2023.02.19.23286158 A1 Shanthini, Thamaraiselvan A1 Manohar, Prasanth A1 Hua, Xiaoting A1 Leptihn, Sebastian A1 Nachimuthu, Ramesh YR 2023 UL http://medrxiv.org/content/early/2023/02/23/2023.02.19.23286158.abstract AB Klebsiella pneumoniae is one of the significant opportunistic pathogens which cause both nosocomial and community-acquired infections. This study focuses on the molecular characterization of hypervirulent K. pneumoniae isolated from clinical samples in Tamil Nadu. A total of 30 clinical K. pneumoniae isolates were collected from the diagnostic centres located in Trichy, Madurai, and Chennai. On subjected to the antibiotic susceptibility testing, it was found that 73% were multi-drug resistant. The string test showed that 46.6% of the isolates were hypermucoviscous (HMV). Molecular studies revealed the absence of mcr (1-5) genes. The isolates belonging to capsular types K1 (n=5), K2 (n=6) and K5 (n=2) were detected. Virulence genes namely rmpA (n=5), aerobactin (n=8), and KfuBC (n=8) were identified using multiplex polymerase chain reaction. Through molecular studies, 22 isolates were found to be classical K. pneumoniae (cKP) and 8 were hypervirulent K. pneumoniae (hvKP). The genome sequencing of five isolates revealed that the strains belong to ST86 and ST23. In vivo studies using Galleria mellonella showed that HMV-hvKP strains were highly pathogenic among the hvKP strains and the non-K1/K2 and K2 strains were pathogenic among the cKP strains. Our data revealed the emergence of colistin-resistant hvKP strains in Tamil Nadu, India.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Vellore Institute of Technology, Institutional Ethical Committee for the studies on Human subjects (IECH) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA838492